A New Approach to Treating Vancomycin-Resistant Enterococcus (VRE)

ACX-375C is an analogue of ACX-362E and has the same novel mechanism of action as a DNA inhibitor of the polymerase III target enzyme.  Limited microbiology data, or MIC data,  demonstrate activity of ACX-375C to certain gram-positive bacteria, including VRE, which is the primary target bacteria for future development efforts.  Initially and if approved, the Company targets ACX-375C as a parenterally administered antibiotic.

Acurx acquired the worldwide rights to ACX-375C from GLSynthesis Inc. in February 2018.

About Vancomycin-Resistant Enterococci

VRE is one of the most common bacteria that cause infections in healthcare facilities in the U.S. according to the Centers for Disease Control and Prevention, or “CDC.”  The CDC has classified VRE bacteria as a serious threat to public health where there are few or no treatment options for certain illnesses including bloodstream infections, surgical site and urinary tract infections.

According to the CDC, the incidence of VRE is approximately 20,000 patients per year in the U.S. alone. Clinical indications include patients with urinary tract infections, catheter/bloodstream infections and intra-abdominal infections. 

About Vancomycin-Resistant Enterococci


Review scientific publications about Vancomycin-Resistant Enterocci (VRE) to get a deeper understanding and the potential of ACX-375C for VRE.

View Publications